Thursday March 3, 2016


  • Matrix vesicles and calcification

    Vicky Macrae, Edinburgh, Scotland

  • Hydrogen sulfide: a novel regulator of joint inflammation and calcification

    Sonia Nasi, Lausanne, Switzerland

  • ABCC6: a new paradigm in calcifying arterial diseases

    Georges Leftheriotis, Angers, France

  • Calcification: related Diseases and Osteoarthritis: cartilage calcification - a systemic process?

    Thelonius Hawellek, Hamburg, Germany

  • Arterial calcification: lessons learned from rare diseases

    Frank Rutsch, Munster, Germany

  • ABCC6 deficiency promotes Randall’s plaque formation in mice

    Emmanuel Letavernier, Paris, France

  • Mineral characterization in rare enamel kidney syndrome related to FAM20A gene mutation

    Ariane Berdal, Paris, France

  • The functional impact of missense mutations in the gene for ecto-nucleotide pyrophosphatase/ phosphodiesterase 1 (ENPP1)

    Yvonne Nitschke, Münster, Germany

  • Report from G-CAN: new global opportunities for networked collaborative research in gout, hyperuricemia, and crystal arthropathy

    Bob Terkeltaub, San Diego CA, USA



  • Genome-wide association studies in gout

    Tony Merriman, Dunedin, NewZealand

  • Obesity and hyperuricemia

    Véronique Vitart, Edinburgh, Scotland

  • Recent advances in the ABCG2 gene and gout

    Tony Merriman

  • Dementia and hyperuricemia

    Tony Merriman

  • Pharmacogenomics of HLA-5801 and Racial Disparities in Allopurinol Hypersensitivity Syndrome

    Hyon Choi, Boston MA, USA

  • Next generation genetics- in silico gout GWAS and sequencing in extreme urate

    Eli Stahl, New York NY, USA

  • Friday March 4, 2015

  • INFLAMMATION (part 1) and GOUT MANAGEMENT (part 1)

  • IL-1 or IL-1 family members in inflammation.

    Charles Dinarello, Aurora, CO, USA

  • IL-37: A new anti-inflammatory strategy in gouty arthritis

    Leo Joosten, Nijmegen, The Netherlands

  • Arhalofenate in gout

    Pol Boudes, Newark, CA, USA

  • Barriers to care of gout and possible solutions to address these

    Michael Doherty, Nottingham, United Kingdom

  • Therapeutic inertia

    Frédéric Lioté, Paris, France

  • Implementation of recommendations Selected Abstracts-2

    Abhishek Abhishek, Nottingham, United Kingdom

  • Suppression of monosodium urate crystal-induced cytokine production via inhibition of histone deacetylases 1 and 2

    Maartje Cleophas, Nijmegen, The Netherlands

  • Patients with gout adhere to long-term urate lowering treatment if informed appropriately : 5 year follow up of a proof-of-concept study.

    Abhishek Abhishek, Nottingham, United Kingdom

  • Medication taking behavior of allopurinol treatment among patients with gout: a retrospective cohort study in the clinical practice research datalink (CPRD).

    Lieke E.J.M. Scheepers, Maastricht, The Netherlands


  • INFLAMMATION (part 2) and GOUT MANAGEMENT (part 2)

  • Allopurinol dose adjustment in CKD: Safe or unsafe ?

    Lisa Stamp & , Otago, New Zealand , Pascal Richette

  • Necroptosis and gout.

    Martin Hermann, Erlangen, Germany

  • Mechanisms of inflammation triggered by endogenous signals

    Fabio Martinon, Lausanne, Switzerland

  • Mitochondrial genetic variation and susceptibility to gout in Polynesians

    Anna Gosling, Dunedin, New Zealand

  • Performance of the 2015 ACR-EULAR classification criteria for gout in a primary care population

    Hein Janssens, Nijmegen, the Netherlands

  • Early pathogenic changes in uremic medial vascular calcification

    Luis Hortells, Zaragoza, Spain